AstraZeneca: Saxa-dapa might be approved this week

BUY, Fair Value  5400p (+30%)
News published on October Monday 12, 2015
Share on

Saxa-dapa is a key asset for AZN’s diabetes franchise which could be approved in the US as early as this week. In April 2014, AZN said it could be a USD3bn opportunity. We are not yet at this level but an approval would be a clear incentive for AZN to support its diabetes franchise further.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities